Stock WILEX AG
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Company Wilex AG Xetra

Equities

DE0006614720

Biotechnology & Medical Research

End-of-day quote Xetra
Other stock markets
- EUR - Intraday chart for Wilex AG
07-11 Heidelberg Pharma AG Reports Earnings Results for the Half Year Ended May 31, 2024 CI
04-25 Heidelberg Pharma AG Reports Earnings Results for the First Quarter Ended February 29, 2024 CI

Business Summary

Heidelberg Pharma AG, formerly Wilex AG, is a Germany-based Company, which is engaged in the biopharmaceuticals sector. The Company focuses on the research and development of therapy treatments for oncology area. It aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Company’s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. It also offers preclinical contract research services.

Sales per Business

EUR in Million2022Weight2023Weight Delta
Antibody Drug Conjugates
100.0 %
19 100.0 % 10 100.0 % -46.75%

Sales per region

EUR in Million2022Weight2023Weight Delta
China
48.1 %
8 44.3 % 5 48.1 % -42.22%
United States
47.4 %
9 48.5 % 5 47.4 % -47.98%
Rest of the World
2.5 %
1 3.9 % 0 2.5 % -66.71%
Switzerland
1.5 %
0 0.3 % 0 1.5 % +178.85%
Germany
0.6 %
1 3.0 % 0 0.6 % -89.07%

Managers

Managers TitleAgeSince
Andreas Pahl CEO
 Chief Executive Officer - 31/12/11
Walter Miller DFI
 Director of Finance/CFO - 30/04/23
András Strassz CTO
 Chief Tech/Sci/R&D Officer - 28/02/21
Jörg Kemkowski COO
 Chief Operating Officer - 31/12/22
Sylvia Wimmer IRC
 Investor Relations Contact - 30/11/99
George Badescu PRN
 Corporate Officer/Principal - 31/10/21

Members of the board

Members of the board TitleAgeSince
Friedrich von Bohlen und Halbach BRD
 Director/Board Member 61 28/04/05
Georg F. Baur BRD
 Director/Board Member 74 13/12/00
Birgit Kudlek BRD
 Director/Board Member 57 24/05/12
Christof Hettich CHM
 Chairman 64 20/05/10
Mathias Hothum BRD
 Director/Board Member 58 29/07/15
Dong Zhou Liu BRD
 Director/Board Member - 27/06/22

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 46,604,977 9,027,536 ( 19.37 %) 0 19.37 %

Shareholders

NameEquities%Valuation
dievini Hopp BioTech holding GmbH & Co. KG
45.70 %
21,296,701 45.70 % 60 M €
HUADONG MEDICINE CO., LTD
35.00 %
16,310,383 35.00 % 46 M €
Universal-Investment-Gesellschaft mbH (Invt Mgmt)
0.5279 %
245,997 0.5279 % 693 392 €
Gutmann Finanz Strategien AG
0.007296 %
3,400 0.007296 % 9 584 €

Company contact information

Heidelberg Pharma AG

Gregor-Mendel-Strasse 22

68526, Ladenburg

+49 6203 1009 0

http://heidelberg-pharma.com
address Wilex AG

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+20.03% 126B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+23.61% 118B
ARGENX SE Stock argenx SE
+23.26% 27.87B
BIONTECH SE Stock BioNTech SE
-18.07% 20.95B
GENMAB A/S Stock Genmab A/S
-15.13% 16.92B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.81% 16.18B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+9.78% 14.84B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-46.10% 14.79B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+52.34% 14.08B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. HPHA Stock
  4. Stock
  5. Company Wilex AG